Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.52 |
| ▸ | SGK1 | O00141 | 2/20 | 0.51 |
| ▸ | F11 | P03951 | 8/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804556 | 0.82 | F11 (0.43) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL4803815 | 0.80 | F11 (0.50) | F11 | |
| SCHEMBL14063588 | 0.79 | PDPK1 (0.53) | JAK2MKNK1MKNK2SGK1PDPK1 | |
| SCHEMBL2334794 | 0.79 | MKNK1 (0.42) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL3174554 | 0.79 | JAK2 (0.56) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL3168797 | 0.78 | JAK2 (0.62) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL3177340 | 0.78 | JAK2 (0.62) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL3173840 | 0.78 | JAK2 (0.62) | JAK2MKNK1MKNK2SGK1F11 | |
| SCHEMBL2334790 | 0.78 | F11 (0.62) | F11PRSS1PRSS2PRSS3KLKB1 | |
| SCHEMBL3169617 | 0.77 | JAK2 (0.53) | JAK2MKNK1MKNK2SGK1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | F12, F11, F2 | JAK2 747/4885MKNK1 1920/4885MKNK2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.